Lanreotide Zentiva (Lanreotide)

• Lanreotide is a somatostatin analog used to treat conditions driven by excess hormone secretion.
• Acromegaly: reduces growth hormone levels and helps control disease progression.
• Neuroendocrine tumors (gastroenteropancreatic NETs): suppresses tumor growth and hormone hypersecretion.
• Carcinoid syndrome: alleviates flushing and diarrhea by inhibiting serotonin release.

• Lanreotide binds with high affinity to somatostatin receptor subtypes 2 and 5 on target cells, mimicking endogenous somatostatin. This interaction inhibits adenylate cyclase activity, reduces calcium influx, and suppresses the release of growth hormone, insulin, glucagon, and various peptide hormones, thereby limiting tumor proliferation and hormone‑mediated symptoms. The prolonged receptor activation leads to sustained downstream signaling inhibition, providing continuous therapeutic effect.

Lanreotide may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Injection site reactions: pain, erythema, or induration at the injection site.
• Gastrointestinal disturbances: nausea, abdominal pain, or diarrhea.
• Gallbladder abnormalities: biliary sludge or gallstones.
• Hyperglycemia: elevated blood glucose levels, especially in diabetic patients.

Serious or Rare Side Effects

• Pancreatitis: inflammation of the pancreas, presenting with severe abdominal pain.
• Allergic reactions: anaphylaxis, urticaria, or angioedema.
• Cardiac arrhythmias: rare cases of bradycardia or conduction disturbances.

When using Lanreotide, several safety considerations should be observed.

• Monitor glucose: check blood sugar levels regularly, especially in patients with diabetes.
• Assess gallbladder: periodic imaging is recommended to detect sludge or stones.
• Pregnancy and lactation: use only when clearly needed; safety data are limited.
• Concomitant medications: evaluate drugs that may alter glucose or gastrointestinal function.
• Discontinuation: do not stop abruptly; taper according to physician guidance.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can interact with other medicines, requiring attention to avoid or monitor effects.

Major Interactions (Avoid)

• Other somatostatin analogs (e.g., octreotide): additive hormone suppression may increase risk of severe hypoglycemia.
• Strong CYP inhibitors: may raise lanreotide plasma levels, though metabolism is limited, caution is advised.
• Gallbladder motility agents: may exacerbate biliary sludge or gallstone formation.

Moderate Interactions (Monitor Closely)

• Antidiabetic agents: monitor for hyperglycemia and adjust doses as needed.
• Gastrointestinal motility drugs: may worsen GI side effects such as nausea or constipation.
• Hormonal contraceptives: possible reduction in efficacy; consider alternative contraception methods.